SymBio Pharmaceuticals - Treakisym has positive DLBCL results
On 5 November 2019, SymBio announced it obtained positive results in its pivotal Phase III clinical trial of Treakisym (bendamustine) in patients...
1.7k Views
SymBio Pharmaceuticals - Preparing to establish own sales organisation
SymBio announced in October that it has begun preparations to establish its own sales organisation to market Treakisym and other anticancer drugs...
124 Views
Japan Fortnightly Update: Spiked
SHORT-LIVED - The much-lauded 'breakout' in the Nikkei 225 (NKY INDEX) at the end of last month proved to be short-lived. As measured by Total...
570 Views
Symbio Confirms Treakisym’s In-House Commercialization Post Patent Expiration in 2020e
Significantly reduces execution risk for an operational turnaround in 2021e As highlighted in previous notes ("Symbio Pharma (4582 JP) - Gross...
385 Views
Treakisym to Be Used as a Pre-Treatment To CAR-T Therapy
Announcement – Symbio Pharmaceuticals (4582 JP) on September 27, 2018, announced that it has filed a partial change application for marketing...
906 Views